Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase
The development of potent, orally bioavailable (in rat) and selective dihydroquinazolinone inhibitors of p38α MAP kinase is described. These analogues are hybrids of a pyridinylimidazole p38α inhibitor reported by Merck Research Laboratories and VX-745. Optimization of the C-5 phenyl and the C-7 pip...
Gespeichert in:
Veröffentlicht in: | Bioorganic & medicinal chemistry letters 2003-01, Vol.13 (2), p.277-280 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The development of potent, orally bioavailable (in rat) and selective dihydroquinazolinone inhibitors of p38α MAP kinase is described. These analogues are hybrids of a pyridinylimidazole p38α inhibitor reported by Merck Research Laboratories and VX-745. Optimization of the C-5 phenyl and the C-7 piperidinyl substituents led to the identification of
15i which gave excellent suppression of TNF-α production in LPS-stimulated whole blood (IC
50=10
nM) and good oral exposure in rats (F=68%, AUCn PO=0.58
μM h).
Graphic |
---|---|
ISSN: | 0960-894X 1464-3405 |
DOI: | 10.1016/S0960-894X(02)00752-7 |